The patient's cancer responded to rechallenge with BRAF- and EGFR-targeted therapy with a rapid decline in CA19-9 levels, BRAF-V600E allele frequencies (0.3%-0.4%), as well as a radiographic response of the new lesions (Figs 1 and 3). The gene discussed is BRAF; the disease is cancer.